<DOC>
	<DOC>NCT01305122</DOC>
	<brief_summary>This is a multicenter prospective study:2 independant cohorts of patients with OMS grade II glioma will be followed during 5 years. - cohort A: patients in first-line treatment (surgery, radiotherapy or chemotherapy) - cohort B: patients with disease simple monitoring. The primary endpoint is to evaluate the impact of tumor and treatments on neurocognitive functions and quality of life, using validate and standard tests.</brief_summary>
	<brief_title>Tumor and Treatments Impact on Neurocognitive Functions and Quality of Life of Patients With OMS Grade II Glioma</brief_title>
	<detailed_description />
	<mesh_term>Glioma</mesh_term>
	<criteria>OMS grade II glioma signed informed consent age &gt;=18 IK &gt;=80% ability to read, write and undertand French glioma localized to brainstem other neurologic or psychiatric disease history of other malignancies, other than curatively treated insitu carcinoma of the cervix or basal cell carcinoma of the skin, or any other curatively treated cancer with no sign of recurrence within 5 years prior to randomization neuroleptic concomitant treatment pregnant or lactating women</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Glioma</keyword>
	<keyword>Neurocognitive functions</keyword>
</DOC>